Monday, September 26, 2016 4:47:38 PM
The problem is that they put out a lot of convertible debt right after that and the stock has plummeted from a high of $0.27 in the summer of 2015 to a low of about $0.005 in the last month or so - - - with outstanding shares around 210M now - about 80M in the float.
All of this sounds depressing, but I think about 2 things when I look at future growth:
- In 2009, with a similar share structure, the stock hit $0.99 per share and stayed in the $0.70-$0.80 range. That was all on only about $500K in sales with Cobroxin hitting the market. Any sales growth of Nyloxin or Pet Pain-Away could see real growth.
- If they can just get that Phase II study underway, they could easily receive a valuation of $100-$150M, or at least $0.50 per share.
I'm still a true believer. I love their products and their technology makes sense. I think that we'll see appreciation soon. JMHO-GLTYA
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM